Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar-Apr;16(2):43-8.
doi: 10.1155/2009/282540.

Amiodarone pulmonary toxicity

N Wolkove  1 , M Baltzan
Affiliations
Review

Amiodarone pulmonary toxicity

N Wolkove et al. Can Respir J. 2009 Mar-Apr.

Abstract
in English, French

Amiodarone is an antiarrhythmic agent commonly used to treat supraventricular and ventricular arrhythmias. This drug is an iodinecontaining compound that tends to accumulate in several organs, including the lungs. It has been associated with a variety of adverse events. Of these events, the most serious is amiodarone pulmonary toxicity. Although the incidence of this complication has decreased with the use of lower doses of amiodarone, it can occur with any dose. Because amiodarone is widely used, all clinicians should be vigilant of this possibility. Pulmonary toxicity usually manifests as an acute or subacute pneumonitis, typically with diffuse infiltrates on chest x-ray and high-resolution computed tomography. Other, more localized, forms of pulmonary toxicity may occur, including pleural disease, migratory infiltrates, and single or multiple nodules. With early detection, the prognosis is good. Most patients diagnosed promptly respond well to the withdrawal of amiodarone and the administration of corticosteroids, which are usually given for four to 12 months. It is important that physicians be familiar with amiodarone treatment guidelines and follow published recommendations for the monitoring of pulmonary as well as extrapulmonary adverse effects.

L’amiodarone est un antiarythmique couramment utilisé pour traiter les arythmies supraventriculaires et ventriculaires. Ce médicament renferme de l’iode qui a tendance à s’accumuler dans plusieurs organes, notamment dans les poumons. Il a été associé à divers effets indésirables, dont le plus grave est la toxicité pulmonaire induite par l’amiodarone. Bien que l’incidence de cette complication ait diminué grâce à la réduction des doses d’amiodarone employées, elle peut survenir à n’importe quelle dose. Étant donné que l’amiodarone est couramment utilisée, tous les médecins doivent rester à l’affût de cette complication possible. La toxicité pulmonaire se manifeste habituellement sous la forme d’une pneumonie aiguë ou subaiguë, généralement accompagnée d’infiltrats diffus à la radiographie pulmonaire et à la tomodensitométrie haute résolution. D’autres formes plus localisées de toxicité pulmonaire s’observent aussi parfois, notamment une atteinte pleurale, des infiltrats migratoires et des nodules simples ou multiples. Un dépistage précoce améliore le pronostic et la plupart des patients chez qui le diagnostic est posé sans retard répondent bien à l’arrêt de l’amiodarone et à l’administration de corticostéroïdes, habituellement pendant quatre à 12 mois. Il est important que les médecins soient renseignés sur les directives thérapeutiques relatives à l’amiodarone et suivent les recommandations publiées pour la surveillance des effets secondaires pulmonaires et autres.

PubMed Disclaimer

Figures

Figure 1)
Figure 1)
Lung parenchyma showing interstitial inflammation and thickening with fibroblastic tissue in airway lumens consistent with organizing pneumonia (arrow) (hematoxylin and eosin stain, original magnification ×100)
Figure 2)
Figure 2)
Microscopic image of an alveolus showing interstitial inflammation and type II pneumocyte hyperplasia. The pneumocytes show many coarse cytoplasmic vacuoles (arrow) (hematoxylin and eosin stain, original magnification ×400)
Figure 3)
Figure 3)
Posterior-anterior chest radiograph of a 79-year-old woman with amiodarone pulmonary toxicity. Bilateral patchy airspace and interstial infiltrates are seen
Figure 4)
Figure 4)
Computed tomography scan of the same patient as seen in Figure 3. A Upper lobe cut shows bilateral patchy infiltrates with some areas of ground glass opacification (G). B A lower lobe computed tomography cut shows bilateral basilar infiltrates and small pleural effusions. Complete resolution occurred after withdrawal of amiodarone and institution of corticosteroids
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vassallo P, Trohman RG. Prescribing amiodarone. JAMA. 2007;298:1312–22. - PubMed
    1. Ernawati DF, Stafford L, Hughes FD. Amiodarone – Induced pulmonary toxicity. BR J Clin Pharmacol. 2008;66:82–7. - PMC - PubMed
    1. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007;356:935–41. - PubMed
    1. Siddoway L. Amiodarone: Guidelines for use and monitoring. Am Fam Physician. 2003;68:2189–96. - PubMed
    1. Primeau R, Agha A, Giorgi C, et al. Long term efficacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol. 1989;5:98–104. - PubMed

Publication types

MeSH terms